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Summary
Placebo analgesia and reward processing share
several features. For instance, expectations have a
strong influence on the subsequent emotional experi-
ence of both. Recent imaging data indicate similari-
ties in the underlying neuronal network. We hypothe-
sized that placebo analgesia is a special case of
reward processing and that placebo treatment could
modulate emotional perception in the same way as
does pain perception. The behavioral part of this
study indicates that placebo treatment has an effect
on how subjects perceive unpleasant pictures. Fur-
thermore, event-related fMRI demonstrated that the
same modulatory network, including the rostral ante-
rior cingulate cortex and the lateral orbitofrontal cor-
tex, is involved in both emotional placebo and pla-
cebo analgesia. These effects were correlated with
the reported placebo effect and were predicted by the
amount of treatment expectation induced on a previ-
ous day. Thus, the placebo effect may be considered
to be a general process of modulation induced by the
subjects’ expectations.
Introduction
The neuroscientific basis of placebo analgesia was
firmly established when Levine et al. (Levine et al.,
1978) discovered that the placebo response could be
blocked using the opioid receptor antagonist naloxone,
indicating involvement of the endogenous opioid sys-
tem. Following this finding, complex experimental de-
signs have elucidated several components underlying
the placebo analgesia response. For instance, a robust
and replicable correlation has been shown between
the degree of expected efficiency of the treatment
(treatment expectation) and the reported decrease in
pain rating following placebo treatment (placebo-induced
analgesia) (Price, 1999; Wall, 1999). One strategy for in-
duction of treatment expectations has been to lower
the noxious stimulation level (after an initial exposure)
when a nonspecific treatment, i.e., placebo, was ap-
plied, without informing the subjects about this pro-
cedure (Montgomery and Kirsch, 1997; Price et al.,
1999; Voudouris et al., 1989; Voudouris et al., 1990). Af-
ter the learning phase, a new placebo treatment was*Correspondence: predrag.petrovic@cns.ki.sefollowed by a noxious stimulation that was once again
set to the pretreatment level. The placebo effect was
highly enhanced compared to when no such prior
manipulation was performed (Voudouris et al., 1989;
Voudouris et al., 1990) or when the subjects were fully
informed about the manipulation (Montgomery and
Kirsch, 1997). Another strategy to induce treatment ex-
pectation has been to first induce analgesia with a spe-
cific drug (e.g., an opioid) and to then administer a pla-
cebo treatment, informing the subjects that the same
drug was used although it actually consisted of a non-
specific treatment (Amanzio and Benedetti, 1999). Both
strategies are much more effective than just informing
subjects falsely about the efficiency of a treatment,
i.e., placebo without any active manipulation. In other
words, placebo has been shown to be crucially depen-
dent on learning effects. This is exemplified by the
strong correlation between treatment expectations and
the placebo effect (Price et al., 1999).
Expectations are fundamental in all emotional pro-
cesses, allowing the individual to interact with an up-
coming emotional or motivational situation before it
actually occurs. It has been postulated that the ventral
tegmental area (VTA) modulates a reward network, in-
cluding the amygdala, the orbitofrontal cortex (Obfc),
the anterior cingulate cortex (ACC), and the striatum,
through dopaminergic projections in order to accom-
plish reward learning (Schultz, 2002). One critical com-
ponent in this process is reward expectation, which
includes a similar dopamine-dependent activation in
part of this network during the anticipation phase. The
neural correlate of expectation has been shown in sev-
eral functional imaging studies of emotion in general,
and of reward processing specifically (Breiter et al.,
2001; Ernst et al., 2004; Gottfried et al., 2003; Kirsch et
al., 2003; Knutson et al., 2001; O’Doherty et al., 2002;
Ramnani and Miall, 2003; Schaefer et al., 2002; Ueda et
al., 2003). It has been suggested that the ventral stria-
tum responds in a linear fashion to the degree of the
reward both during the anticipatory (Breiter et al., 2001;
Ernst et al., 2004; Knutson et al., 2001) and the reward
phase (Breiter et al., 2001). However, functional imaging
studies have also implicated the ACC, the Obfc, and
the amygdala in reward expectation (Breiter et al., 2001;
Ernst et al., 2004; Knutson et al., 2001; Gottfried et al.,
2003; O’Doherty et al., 2002).
Reward processing also includes components other
than learning, such as motivational and affective-emo-
tional processes (Berridge and Robinson, 2003). Simi-
larly, apart from being important for learning, reward
expectation has a direct effect on the emotional expe-
rience. Different reward expectations and outcomes
directly influence how we feel and how a subsequent
specific stimulation is emotionally experienced (Mel-
lers, 2000). The rationale for the direct effect of reward
expectation on emotional experience may be interpre-
ted in the light of emotional experience being a bias
signal for cognitive processes (Bechara et al., 1997; Da-
masio, 1996).
Recently, functional imaging studies have described
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958underlying neuronal networks involved in the placebo a
analgesia process (Lieberman et al., 2004; Petrovic et O
al., 2002; Wager et al., 2004) and their effect on the
pain matrix (Lieberman et al., 2004; Wager et al., 2004), a
although no relationship has yet been proven between s
treatment expectation and the placebo response in the c
brain. Pain is a composite perception and includes sen- d
sory, motivational, and central control processing (Mel- a
zack and Casey, 1968). The medial pain system, which a
includes the ACC and the insula, is thought to be in- g
volved in the emotional-motivational aspect of pain s
processing (Vogt et al., 1993). Regions activated by t
noxious stimulation and specifically belonging to the i
medial pain system (Peyron et al., 2000; Vogt et al., 2
1993) are also involved in the processing of more ab- m
stract derivates of pain, such as anticipation of pain o
(Hsieh et al., 1999; Jensen et al., 2003; Koyama et al., a
1998; Ploghaus et al., 1999), empathy for pain (Singer a
et al., 2004), and social exclusion (Eisenberger et al., t
2003). Moreover, a similar network takes part in the pro- c
cessing of unpleasant emotions (Phillips et al., 2003). c
Apart from the involvement of similar regions in the pro- t
cessing of pain and emotion, both placebo analgesia a
(Lieberman et al., 2004; Petrovic et al., 2002; Wager et G
al., 2004) and emotional regulation (Bishop et al., 2004; a
Ochsner et al., 2002) are associated with increased c
activation in a modulatory network that includes the l
rostral ACC (rACC) and the ventrolateral prefrontal cor- p
tex (vlPFC)/lateral Obfc (lObfc). This suggests a func- e
tional-anatomical relationship between placebo anal- p
gesia and emotional regulation in which a top-down
modulation of the pain or emotional network is imple- R
mented.
There are thus similarities between placebo analge- W
sia and reward processing, especially as both involve t
anticipation of a positive outcome and are highly de- c
pendent on expectations. The main difference is that (
the concept of a placebo effect involves a reduced a
aversion, while the reward concept is associated with m
a pleasant experience. Here we suggest that placebo c
analgesia is actually a special case of reward process-
d
ing, in agreement with recent theoretical considerations
a
(Fields 2004; Vase et al. 2004). If this is the case, the
wmechanisms underlying the placebo analgesia effect
tmust be viewed as a general process not specifically
scoupled to pain. We therefore suggest that the placebo
rphenomenon may be applied to any emotional experi-
ence. To test this hypothesis, we probed for placebo
Eeffects in the setting of unpleasant emotional experi-
oence induced by standardized affective pictures. In or-
Ader to generate a strong placebo effect, we induced
Oa treatment expectation in the group of participating
bsubjects 1 day prior to the test day using drugs that
phave well-described specific effects on the emotional
texperience (anxiolytic drug and blocker of the anxio-
clytic drug). This procedure was termed an “expectation
tmanipulation” in analogy with previous similar active
vmanipulations preceding placebo analgesia (Amanzio
fand Benedetti 1999; Montgomery and Kirsch, 1997;
(Price et al., 1999; Voudouris et al., 1989; Voudouris et
ral., 1990). On day 2, we tested for behavioral placebo
deffects and whether the same underlying network was
minvolved in emotional placebo as in placebo analgesia
(Lieberman et al., 2004; Petrovic et al., 2002; Wager et nl., 2004) and emotional regulation (Bishop et al., 2004;
chsner et al., 2002) using event-related fMRI.
Visual processing of complex emotional situations
nd faces, especially fearful and threatening visual
timuli, involves activation of an emotional network in-
luding the extrastriate cortex and the amygdala (Ge-
ay et al., 2003; Surguladze et al., 2003; Vuilleumier et
l., 2001). Top-down modulation of perceptions is often
n effect of regulation through secondary sensory re-
ions and limbic networks (Mesulam, 1998). Previous
tudies have indicated that the extrastriate cortex and
he amygdala are prone to such top-down modulations
n emotional processing of visual stimuli (Hariri et al.,
003; Ochsner et al., 2002; Pessoa et al., 2002; Vuilleu-
ier et al., 2001). Thus we hypothesized that activation
f the extrastriate cortex and the amygdala should be
ttenuated, while activation of the prefrontal regions
nd the rACC should be augmented by the placebo
reatment in the present study of visual emotional pro-
essing. If these physiological effects truly mirror a pla-
ebo mechanism, they should also be most evident in
he subjects that demonstrated the strongest behavior-
lly measured placebo response (Wager et al., 2004).
iven the relationship between treatment expectation
nd placebo response, we also tested whether the pla-
ebo-dependent responses in the brain directly corre-
ated with the degree of expectation. The degree of ex-
ectation was approximated to the reported behavioral
ffect of the specific treatment preceding the placebo
rocedure.
esults
e enrolled 15 healthy subjects in a 2 day experiment
o study the placebo effect on visual emotional pro-
essing using a set of standardized affective pictures
IAPS) (Lang et al., 1995). On the first day, anxiolytic
nd anxiolytic-blocker drugs were used in order to
odulate the experience of unpleasant pictures. Spe-
ific treatment induced an expectancy effect for the
rugs, which is an important factor in the induction of
placebo response. On the second day, the subjects
ere treated with the placebo while viewing the same
ype of unpleasant pictures. The underlying neural re-
ponse was simultaneously measured using event-
elated fMRI.
xpectation Manipulation on Day 1—Effects
f Benzodiazepine and Benzodiazepine
ntagonists on Emotional Perception
n day 1, the subjects were shown three presentation
locks (with a duration of approximately 5 min each) of
seudorandomly mixed unpleasant and neutral pic-
ures. The subjects were asked to rate the mean per-
eived unpleasantness of the viewed unpleasant pic-
ures at the end of each presentation block using a
isual analog scale ranging from 0 to 100. After the
irst presentation in which no drugs had been given
presentation block 1; unpleasantness rating = 51.0;
ange = 30–76), the subjects were treated with a low
ose of benzodiazepine intravenously (midazolam, 0.015
g/kg), which dramatically decreased the unpleasant-
ess rating in each subject during the second presenta-
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29.0; range = 8–52) (Figure 1A). This effect was com-
pletely reversed in the third presentation (presentation
block 3; unpleasantness rating = 60.9; range = 25–88)
for all subjects by pretreating them intravenously with
a benzodiazepine receptor antagonist (flumazenil, 0.25
mg) (Figure 1A). The subjects were informed of the pos-
sible effect of the anxiolytic and the anxiolytic blocker
drugs on their perception of emotions before the exper-
iment and before each picture presentation block.
Thus, on the first day a robust expectation of the treat-
ment effect was induced (i.e., the experience of the
drug treatment and the given information), which is an
important component in the placebo response. The
subjects were further told that both the anxiolytic drug
and the anxiolytic blocker would be used again on day
2 in the fMRI experiment.
Placebo Manipulation on Day 2—Effects
of Placebo on Emotional Perception
On day 2, the subjects underwent the event-related
fMRI study of the placebo effect on emotional process-
ing. The subjects were told that they would be treated
either with the same anxiolytic drug or the anxiolytic
blocker prior to presentation of unpleasant and neutral
pictures as during the previous day. They were also ex-
plicitly informed via a computer screen about the up-
coming treatment before each visual presentation com-Figure 1. Experimental Design and Behav-
ioral Results
(A) In order to induce a treatment expecta-
tion, the individuals were subjected to three
conditions on day 1 (expectation manipula-
tion). In each condition, they watched different
presentation blocks consisting of unpleasant
and neutral pictures (IAPS [Lang et al., 1995]).
After each presentation block, they rated the
perceived average unpleasantness induced
by the unpleasant pictures using a VAS
(range 0–100, where 0 indicated no unpleas-
antness and 100 indicated maximally imag-
ined unpleasantness). They were first shown
a presentation block without treatment (pre-
sentation 1; mean rating of unpleasantness =
51.0). In the second condition, the subjects
were treated with the anxiolytic drug mido-
zalam, 0.015 mg/kg intravenously, before the
presentation block (presentation 2; mean
rating of unpleasantness = 29.0). In the third
condition, the subjects were treated with
0.25 mg of flumazenil intravenously before
the third presentation block (presentation 3;
mean rating of unpleasantness = 60.9).
(B) On day 2, the subjects underwent the
placebo fMRI experiment (placebo manipu-
lation). The experiment was divided between
three sessions consisting of two presenta-
tion blocks each presented in a semirandom
order (see Experimental Procedures). Before
the three presentation blocks, the subjects
were informed that they would receive the
same anxiolytic substance as on day 1 (pla-
cebo condition). However, they received 5 ml
of saline intravenously instead. The mean rating of unpleasantness of the placebo sessions was 36.4. The subjects were informed that they
would receive the anxiolytic blocker before the other presentation blocks (control condition). The mean rating of the induced unpleasantness
during the control conditions was 50.9. There was a significant difference between the unpleasantness ratings in the placebo versus the
control condition (p < 0.001; Wilcoxon’s Signed Rank test).menced. However, instead of being treated with the
active drugs, the subjects received intravenous saline
before each presentation block. Thus, when the sub-
jects thought that they had received the anxiolytic drug,
the placebo effect was induced (expectation of anxio-
lytic effect), and when the subjects thought that they
had received the anxiolytic blocker, the control effect
was induced (no expectation of anxiolytic effect). The
fMRI study incorporated three sessions, each session
including one presentation block consisting of ten un-
pleasant and ten neutral pictures following the placebo
treatment (with a duration of approximately 4 min) and
one similar presentation block following control treat-
ment (Figure 1B). Four different event-related condi-
tions were therefore induced in a factorial design: (1)
unpleasant pictures after placebo treatment (UP); (2)
neutral pictures after placebo treatment (NP); (3) un-
pleasant pictures after control treatment (UC); and (4)
neutral pictures after control treatment (NC).
There was a significant and robust placebo response
for the whole group in that viewing of the unpleasant
pictures yielded a 28.6% decrease in the VAS rating of
unpleasantness for the placebo conditions as com-
pared to control conditions (unpleasantness rating in
UC condition = 50.9; and in UP condition = 36.4; p <
0.001, Wilcoxon’s Signed Rank test). During the de-
briefing session, 11 of the 15 subjects reported a clear
subjective decrease in unpleasantness perception dur-
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rof the Same Network
e(A) The emotional network activated by unpleasant versus neutral
pictures in ((UP + UC) − (NP + NC)). f
(B) One of the three regions in the extrastriate cortex belonging to t
the emotional network that showed an attenuated activation during e
placebo versus control stimulation for the unpleasant pictures e(UC − UP) in the group of placebo responders ([50 −56 −14]; t
tvalue = 3.93). The other two activations in the extrastriate cortex in
Uthe same contrast were [X Y Z] = [−38 −74 −26], t = 6.68; and [X Y
Z] = [−52 −70 −6], t = 3.54). p < 0.005, uncorrected.
The t values of the activations are given by the color bar.
M
Ting placebo as compared to control sessions. We w
therefore classified 11 subjects as responders and the i
4 others as nonresponders. v
t
iEffects of Placebo on Emotional Processing
The fMRI data demonstrated an increased activity in a t
avisual emotional network including the extrastriate cor-
tex and the amygdala in response to the emotional pic- in the simple main effect of (UP − UC). Thus, the right
Table 1. Regions Responding to Emotional Pictures
MNI Coordinates
Region X Y Z t Value p Value
Main effect of emotion
(UP + UC) − (NP + NC)
Right primary visual Cortex (BA 17) 16 −92 0 8.86 <0.001
Left primary visual cortex (BA18) −16 −94 12 7.03 <0.001
Left fusiform gyrus (BA 37) −42 −62 −18 9.71 <0.001
Right middle occipital gyrus (BA 19) 48 −70 8 9.89 <0.001
Right fusiform gyrus (BA 37) 44 −60 −22 9.04 <0.001
Left middle occipital gyrus (BA 37) −54 −70 4 6.85 <0.001
Right lingual gyrus (BA 18) 14 −74 −12 6.19 <0.001
Left lingual gyrus (BA 18) −10 −74 −6 4.66 <0.001
Right ACC/SMA (BA 24/6) 6 4 58 4.86 <0.001
Right ACC/SMA (BA 24/6) 4 12 46 3.89 <0.001
Right insula/lObfc (BA 14/47) 36 26 −12 4.83 <0.001
Right amygdala 22 −6 −22 4.07 0.001
Left amygdala −20 −8 −20 3.60 0.001
PAG −2 −30 −8 4.27 <0.001
Right dlPFC (BA 44/45/6) 46 12 20 10.47 <0.001
Left precentral gyrus (BA 6) −54 0 36 3.79 <0.001
Right PPC (BA 19) 30 −74 34 4.63 <0.001
Left precuneus (BA 7) −28 −58 54 4.81 <0.001ures as compared to the neutral pictures (Figures 2A
nd 5A; Table 1). Other regions that were activated in-
luded the ACC, insula, brainstem, dorsolateral PFC,
nd primary visual cortex. This network was classified
s the main effect of emotion. Based on previous
tudies (Hariri et al., 2003; Ochsner et al., 2002; Pessoa
t al., 2002; Vuilleumier et al., 2001), we specifically
ssessed modulations in the higher visual areas and
he amygdala of the functionally defined emotional
etwork.
Our first specific analysis concerned the question of
hether there was a placebo-related attenuation in the
esponse of the emotional network. In accordance with
he behavioral data, the activity in several areas of the
xtrastriate visual areas was significantly decreased in
he placebo condition compared with the blocker con-
ition for the unpleasant pictures (Figure 2B; Tables 2
nd 3). The effect was apparent for both the group con-
isting of all subjects and for the subgroup of placebo
esponders and survived a masking procedure in the
motional network, indicating that the relevant areas
or processing the emotional effect were suppressed in
he placebo condition. The suppressed response of the
xtrastriate cortex in the subtraction analysis was
ven apparent after the nonspecific placebo effects of
he neutral pictures had been cancelled out (i.e., [(UP −
C) − (NP − NC)]) for the placebo responders (Table 3).
odulatory Network underlying the Placebo Effect
he main focus of this study was the modulatory net-
ork involved in the general placebo response, includ-
ng the lObfc and the rACC. The right lObfc was acti-
ated when placebo was compared with the control
reatment after adjusting for nonspecific effects in the
nteraction analysis [(UP − UC) − (NP − NC)], even in
he group comprising all subjects (Figure 3B; Tables 2
nd 3). This effect was also evident for the whole group
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961Table 2. Placebo-Dependent Changes in Neuronal Activity for the Group Comprising All Subjects
MNI Coordinates
Region X Y Z t Value p Value
Placebo-dependent increased activity for the unpleasant
pictures
UP-UC
Right lObfc (BA 10/47) 26 48 −8 3.34 0.002
Right rACC/vmPFC (BA 10) 6 64 8 3.82 0.001
Placebo-dependent increased activity specific
for the unpleasant pictures
(UP − UC) − (NP − NC)
Right lObfc (BA10/47) 28 50 −6 6.08 <0.001
Placebo-dependent decreased activity for the unpleasant
pictures
UC − UP
Left inferior temporal gyrus (BA 37) −48 −64 2 4.13 <0.001
Right fusiform Cortex (BA 37) 46 −54 −16 3.59 0.001
Placebo-dependent increased activity specific
for the unpleasant pictures
(UC − UP) − (NC − NP) — — — — —
n = 15.hemisphere activation of the lObfc, previously shown
for placebo analgesia (Petrovic et al., 2002), was repro-
duced in the present study. Apart from the right Obfc,
the placebo responders also activated the rACC and
the vlPFC in the (UP − UC) and [(UP − UC) − (NP −
NC)] conditions (Figure 3A and Table 3), close to the
activation observed in placebo analgesia (Petrovic et
al., 2002). Placebo-dependent activation of the vlPFC
was specific for the subgroup of placebo responders.
Correlation Analysis between Neuronal
Activity and Ratings of Placebo
The placebo-dependent suppression of activity in the
visual areas directly correlated with the degree of change There was a positive correlation between the re-
Table 3. Placebo-Dependent Changes in Neuronal Activity for the Placebo Responders
MNI Coordinates
Region X Y Z t Value p Value
Placebo-dependent increased activity for the
unpleasant pictures
UP − UC
Left vlPFC (BA 10) −40 54 4 4.85 <0.001
Right rACC/vmPFC (BA 32/10) 18 50 8 3.62 0.002
Placebo-dependent increased activity specific for
the unpleasant pictures
(UP − UC) − (NP − NC)
Right lObfc (BA 47/10) 28 50 −8 5.39 <0.001
Left vlPFC (BA 47/10) −40 52 6 4.37 <0.001
Right vlPFC/dlPFC (BA 47/46) 38 36 10 3.93 0.001
Left rACC (BA 32) −12 48 12 6.17 <0.001
Right rACC/vmPFC (BA 32/10) 12 56 8 3.91 0.001
Placebo-dependent decreased activity for the
unpleasant pictures
UC − UP
Left fusiform gyrus (BA 37/19)/cerebellum 38 −74 −26 6.68 <0.001
Right fusiform gyrus (BA 37) 50 −56 −14 3.93 0.001
Left fusiform gyrus/inferior occipital gyrus (BA 19) −52 −70 −6 3.54 0.003
Placebo-dependent increased activity specific for
the unpleasant pictures
(UC − UP) − (NC − NP)
Right lingual gyrus (BA 19) 14 −62 0 4.33 <0.001
n = 11.in unpleasantness rating due to placebo treatment that
was reported after the fMRI session (Figure 4A and Ta-
ble 4). Subjects that had the largest placebo response
demonstrated the most expressed decreases in the
emotional network. The analysis also showed a correla-
tion between the placebo-related attenuation of the
amygdala/para-amygdaloid complex bilaterally and the
subjective placebo response (Figure 5 and Table 4), i.e.,
the subjects reporting the largest placebo response
had the strongest decreases of activity in this structure.
Thus, both the extrastriate cortex and the amygdala ac-
tivity, which represent important parts of the emotional
network, were modulated by placebo treatment.
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oThe rACC (A) and the right lObfc (B) were activated in the placebo
econdition versus the control condition specifically for the unpleas-
ant pictures ((UP − UC) − (NP − NC)) in the group of placebo re- a
sponders ([28 50 −8], t value = 5.39, and [−12 48 12], t value = 6.17, t
respectively). p < 0.005, uncorrected. The t values of the activations c
are given by the color bar.
a
eence may be modulated through a placebo treatment(UP − UC) did not show any correlation with the sub-
Figure 4. Correlation between Placebo Rating and Placebo Processing
The behavioral placebo effect as rated on day 2 correlated negatively with the BOLD-dependent placebo effect of (UP − UC) in the extrastriate
cortex (A) and positively with the activity in the rACC (B). In (A), one of the four regions correlating negatively with the placebo effect is shown
([38 −76 −16], t value = 4.87). In (B), one of the several regions in rACC ([−10 26 26], t value = 5.75) that correlated positively with the reported
placebo effect is highlighted with a cross. p < 0.005, uncorrected. The t values of the activations are given by the color bar.vported placebo effect and increased activity in several
Tregions of the ACC and vlPFC in (UP − UC) (Figure 4B
and Table 4). Thus, subjects that reported the largest
decreases in unpleasantness after the placebo treat- D
ment also had the most extensive placebo-depen-
dent activation of the ACC. However, Obfc activation in Tective placebo effect, even at an exploratory low
hreshold (p < 0.05, uncorrected).
orrelation Analysis between Neuronal
ctivity and Treatment Expectation
imilar to the placebo effect, the treatment expectation
or the specific treatment correlated with nonspecific
lacebo-dependent decreases in the extrastriate cor-
ex (Figure 6A and Table 5). The degree of decrease in
xtrastriate activity during the placebo treatment (UC −
P) observed during day 2 was most apparent in those
ubjects that had the largest effect with the anxiolytic
reatment on the emotional experience on day 1.
A correlation was also determined between the pla-
ebo-dependent increase in rACC and the treatment
xpectation (Figure 6B and Table 5), i.e., subjects that
ad the strongest effect of the specific anxiolytic treat-
ent on emotional experience day 1 also had the most
xpressed placebo-dependent activation of the rACC
n day 2. One of the correlations between treatment
xpectation and placebo activation was expressed in
n area of the rACC ([X Y Z] = [10 48 14]), very close to
he activations induced by placebo treatment. These
orrelations were observed both in the rACC proper
nd on the border to the caudal ACC. Finally, treatment
xpectation correlated with the placebo-induced acti-
ation (UP − UC) in the ventral striatum (Figure 6C and
able 5).
iscussion
he present data demonstrate that emotional experi-
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MNI Coordinates
Region X Y Z t Value p Value
Placebo effect correlated with (UP − UC)
Right vlPFC (BA 10) 32 46 8 5.89 <0.001
Left vlPFC (BA10) −26 58 10 3.88 0.001
Left rACC (BA 24/32) −10 26 26 5.75 <0.001
Left c/rACC/SMA (BA 32/8) −6 18 46 4.88 <0.001
Right c/rACC (BA 24) 10 10 32 4.75 <0.001
Left rACC (BA 32) −8 32 −4 4.63 <0.001
Right rACC (BA 24) 10 26 16 4.28 0.001
Right rACC (BA 32) 20 32 20 3.91 0.001
Right rACC/vmPFC (BA 32/10) 16 52 16 3.36 0.004
Left insula (BA 13/14) −42 0 10 4.70 <0.001
Right insula (BA 13/14) 40 6 −4 4.49 <0.001
Placebo effect correlated with (UC − UP)
Right fusiform gyrus (BA 19)/cerebellum 44 −60 −28 5.28 <0.001
Right fusiform gyrus (BA 19) 38 −76 −16 4.87 <0.001
Left fusiform gyrus (BA 37)/cerebellum −40 −56 −26 4.47 <0.001
Left fusiform gyrus (BA 37) −42 −52 −22 3.20 0.004
Right amygdala/MTL 34 8 −24 3.79 0.001
Left amygdala/MTL −28 −2 −24 3.50 0.002
The insula was not a part of the predefined network. The post hoc observed activations in this structure are therefore only stated in the table
without any further discussion.in a similar manner as has been previously reported for
pain perception (e.g., Levine et al., 1978; Voudouris et
al., 1990; Montgomery and Kirsch, 1997; Voudouris et
al., 1989; Price et al., 1999; Amanzio and Benedetti,
1999; Lieberman et al., 2004; Petrovic et al., 2002; Wa-
ger et al., 2004). At a neurophysiological level, the data
also suggest that the underlying network processing
the unpleasant stimuli may be suppressed via placebo
treatment. Moreover, this attenuation of activity corre-
lates with the individual placebo response. Thus, sub-
jects that showed the largest placebo response also
demonstrated the most expressed decreases in the
emotional network. This finding mirrors the recently re-
ported correlation between the individually perceived
placebo effect and attenuation of the pain matrix in pla-
cebo analgesia (Wager et al., 2004) and generalizes the
effect to a matrix processing emotional visual stimuli.Figure 5. Placebo Effect on the Amygdala Activity
(A) The amygdala was activated bilaterally in the main effect of
emotion.
(B) The behavioral placebo response on day 2 correlated negatively
with the activity in the amygdala bilaterally during the placebo re-
sponse (UP − UC). The left amygdala had a maximally activated
voxel with the coordinate of [−28 −2 −24] and t value = 3.50, and
the right amygdala had a maximally activated voxel with the coordi-
nate of [34 8 −24] and t value = 3.79. The involved voxels were a
part of the emotional network shown in (A). p < 0.005, uncorrected.
The t values of the activations are given by the color bar.The interaction analysis showed that the placebo treat-
ment specifically affected the unpleasant pictures, indi-
cating that the visual stimuli are categorized into being
unpleasant or neutral before top-down modulation of
the emotional processing is invoked, in accordance
with recent suggestions (Dolan, 2002).
An increased activity was observed in the right lObfc
and the rACC during the placebo response. Thus, a
similar network was activated during the anxiolytic pla-
cebo condition in the present study, as has been pre-
viously shown in placebo analgesia (Petrovic et al.,
2002), suggesting a similar modulatory system for both
placebo conditions. We suggest that the modulatory
processes in placebo are not specific for placebo anal-
gesia, but are rather a part of the mechanisms involved
in the regulation of emotional processes in general (Da-
vidson et al., 2000), including other categories of cogni-
tive modulations of pain (Petrovic and Ingvar, 2002).
However, as stated above, there was a distinction be-
tween the lObfc and the rACC in that only the activation
of the latter correlated with the subjective placebo re-
sponse. This response was expressed somewhat more
caudally in the rACC than in the subtraction analysis.
Finally, the vlPFC showed bilateral placebo-dependent
activation in both the subtraction analysis for the pla-
cebo responders and also correlated positively with the
subjective placebo response.
The behavioral placebo effect has been shown to be
highly dependent on the treatment expectancy that has
previously been induced, either through experimental
manipulation (Montgomery and Kirsch, 1997; Price et
al., 1999; Voudouris et al., 1989; Voudouris et al., 1990)
or through drug treatment (Amanzio and Benedetti,
1999). In agreement with those behavioral experiments,
we observed a correlation between the treatment ex-
pectation (induced day 1) and the placebo-dependent
activity decreases in the fusiform gyrus and increases
in the ACC on day 2 (Figures 6A and 6B). These findings
Neuron
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opredicts the placebo effect at a neuronal level and that
the relationship between the expectation and the pla- e
jcebo response is not simply a behavioral response
bias. It should be noted that treatment expectations a
cwere only indirectly measured in the present study. The
active substance and the suggestions on days 1 and 2 n
sprobably all induced expectations underlying the pla-Table 5. Correlation Analysis between the Treatment Expectation and Placebo-Dependent Neuronal Activity
MNI Coordinates
Region X Y Z t Value p Value
Treatment expectation correlated with (UP − UC)
Left vlPFC (BA 10) −32 48 2 4.77 <0.001
Right c/rACC (BA 24/32) 14 24 32 4.12 <0.001
Right rACC (BA 32) 10 48 14 4.12 <0.001
Right rACC (BA 32) 16 40 −6 4.12 <0.001
Left posterior insula −28 −24 16 3.95 <0.001
Right ventral striatum 20 18 −6 4.12 <0.001
Treatment expectation correlated with (UC − UP)
Right fusiform gyrus (BA 19) 38 −76 −20 4.71 <0.001
The insula was not a part of the a priori defined network. The post hoc observed activations in this structure are therefore only stated in the
table without any further discussion.urements have been successfully used previously
Figure 6. Correlation between Treatment Expectation and Placebo Processing
(A) The treatment effect reported on day 1 correlated negatively with the extrastriate cortex activation in (UP − UC) ([38 −76 −20], t = 4.71
[cross]) and positively (B) with the ACC activation in (UP − UC) ([14 24 32], t value = 4.12 [cross]; [10 48 14], t value = 4.12; [16 40 −6],
t value = 4.12) on day 2. (C). Placebo-dependent activity (UP − UC) in the right ventral striatum induced on day 2 correlated with the treatment
expectation induced on day 1. p < 0.005, uncorrected. The t values of the activations are given by the color bar.ebo effect (Vase et al., 2004). We only used the effect
f treatment on day 1 as a measurement of treatment
xpectation so we did not know exactly what the sub-
ects expected before treatment on day 2. However, we
voided direct rating of treatment expectation since it
ould have induced a suspicion in the subjects that a
onactive agent was actually used (although such mea-
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treatment effect day 1 (in the expectation manipulation)
would give a crude but representative measurement of
the treatment expectation in that the subject that had
experienced the largest treatment effect on day 1 prob-
ably also expected the largest effect on day 2.
A key function of the Obfc is to monitor and modulate
the motivational value of external stimuli based on their
coupling to primary re-enforcers (Gottfried et al., 2003;
Kringelbach and Rolls, 2003; O’Doherty et al., 2001;
Tremblay and Schultz, 1999) in order to perform goal-
directed behavior (Schoenbaum and Setlow, 2001).
Since the Obfc is involved in attributing external stimuli
a relative value depending on the internal states and
external contexts, it is tempting to suggest that this re-
gion is involved in inducing expectation of treatment,
which is an important component in placebo analgesia
(Amanzio and Benedetti, 1999; Price et al., 1999). This
coupling may be used as a blueprint copy to induce the
expected emotional state during a placebo condition
and precedes opioid-dependent modulation of pain
perception. The same hypothesis may be applied for
emotional placebo in the present study. As noted
above, we did not observe any correlation with treat-
ment expectation in this region. However, the influence
from the Obfc that specifically contributes to the down-
stream modulatory control has been suggested to take
part in the preparatory or anticipatory stage of emo-
tional modulation (Bishop et al., 2004; Wager et al.,
2004), which was not measured in the present study.
Thus, our data indicate that the lObfc may take part in
emotional modulation elicited by a placebo, but do not
suggest the direct nature of its involvement. A design
that allows the measurement of the preparatory activity
may define such an involvement of the Obfc in emo-
tional placebo, as previously shown for placebo anal-
gesia (Wager et al., 2004). However, the vlPFC showed
placebo-dependent bilateral activations correlated with
both the placebo effect and the treatment expectation
(left vlPFC). Thus, this region is in a position to process
treatment expectation.
We have previously suggested that the rACC is in-
volved in the interaction between attention and the opi-
oid system in placebo analgesia (Petrovic et al., 2002)
due to the dense concentration of opioid receptors in
the ACC (Vogt et al., 1993) and its involvement in tasks
requiring conflict resolution (Bush et al., 2000; Paus,
2001). The rACC may therefore have a direct influence
on emotional systems using specific neuromodulatory
systems. It is presently unknown whether the opioid or
other specific neuromodulatory systems are similarly
involved in the modulation of pure emotional process-
ing, although it has been suggested that the human
opioid system is directly involved in the processing and
regulation of emotion (Liberzon et al., 2002; Zubieta et
al., 2003). Another potential neuromodulatory system
involved in emotional placebo is the dopamine system,
which is involved in expectations of caffeine in healthy
subjects (Kaasinen et al., 2004) and in treatment expec-
tation in Parkinson’s patients (de la Fuente-Fernandez
et al., 2001). The involvement of the dopamine system
in reward expectation and reward reception in general
(Schultz, 2002) supports this notion.
Although previous studies have implicated rewardexpectation in error learning during motivational tasks
(Schultz, 2002), rewards also affect affective-emotional
processing (Berridge and Robinson, 2003), and antici-
pation of rewards may modulate the subjective emo-
tional experience (Mellers, 2000). This has also clearly
been shown during craving in drug addicts (Pelchat,
2002), and the relationship between emotion and re-
ward-processing may be an important aspect of cogni-
tive processing underlying decision making (Bechara et
al., 1997; Damasio, 1996). The placebo effect is a more
complex process than normal reward expectation since
the subjects never expect to receive a normal reward
but instead a decreased aversive perception. Neverthe-
less, if the placebo effect is viewed as a relative reward
(Fields 2004; Vase et al. 2004) it should comply with
previously shown effects for reward processing. Apart
from influencing the emotional experience of an un-
pleasant stimulation there should be neurophysiologi-
cal similarities with reward processing. The involve-
ment of ACC and Obfc is observed both in reward
processing (Breiter et al., 2001; Ernst et al., 2004; Gott-
fried et al., 2003; Kirsch et al., 2003; Knutson et al.,
2001; O’Doherty et al., 2002; Ueda et al., 2003) and in
placebo processing (Lieberman et al., 2004; Petrovic et
al., 2002; Wager et al., 2004). Another related effect is
evident in the ventral striatum, which directly correlates
with the treatment expectation for the different subjects
(Figure 6C). This corroborates a previously reported
correlation between the striatum activity with reward
value in the anticipatory (Breiter et al., 2001; Ernst et
al., 2004; Knutson et al., 2001) and consumatory phase
(Breiter et al., 2001), although the present activity was
somewhat more rostral. Given the known specific in-
volvement in error prediction of rewards (Schultz, 2002),
this activity may represent the difference between infor-
mation regarding the innate unpleasantness of the
viewed pictures and the expected unpleasant experi-
ence. There is also a clear overlap between networks
in the striatum processing reward and aversive stimuli
(Becerra et al. 2001), making an interaction between re-
wards and aversive perception possible in placebo ma-
nipulation.
Apart from suggesting an underlying neuronal mech-
anism for the placebo effect, a generalized theory of
placebo would benefit from a hypothesis that supports
the evolutionary advantage with a placebo effect. Previ-
ous research has suggested that the placebo effect is
induced by expectations (see above), drug condition-
ing, or a subjective desire for relief (Price, 1999; Wall,
1999). However, none of these theories associates an
evolutionary benefit of the placebo effect. A very impor-
tant principal line of development is the move from re-
active processing toward proactive processing (Fuster,
2004). Proactive processing entails a continuous simu-
lation of the future (Ingvar, 1985), which is a very effec-
tive tool in minimizing computational demands in the
generation of behavior. Thus, an experience may be the
composite of predictive information and incoming stim-
ulation from the internal and external worlds. A well-
studied illustration of this effect supported by experi-
mental behavioral and imaging data is the forward
model, which predicts that self-induced sensations are
cancelled out since they do not contain any more infor-
mation about the world (Blakemore et al., 1998). In anal-
Neuron
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pviewed as a composite experience induced by both the
tlearned expectations and the actual stimulation. The
f
placebo effect could therefore be explained merely as
the subjective experience of the world in which a large
Econtribution derives from previous learning.
OIn conclusion, this study demonstrates that very sim-
i
ilar mechanisms are involved in the placebo response v
of emotional stimuli and in placebo analgesia, thereby r
ageneralizing the concept of placebo and its associated
wunderlying neural processes. Apart from showing that
sthese effects are related to the degree of reported pla-
ocebo effect, this study indicates that they are also pre-
A
dicted by the treatment expectation induced on a previ- m
ous day, linking the placebo effect in general to reward i
dexpectation. The placebo effect can thus be thought
oof as a general process of modulation induced by the
csubjects’ expectations, possibly using specific modu-
flating systems.
5
c
Experimental Procedures p
p
Fifteen female subjects (age ranging from 20 to 33 years) com- d
pleted this 2 day study. They were all right handed according to the m
Edinburgh handedness inventory. They had no history of any major c
psychiatric or neurological conditions. All subjects were healthy 1
and took no medications, except for one allergic subject who used a
a mild asthma inhalation medicine. However, we did not account t
for either menstrual phase or birth control. All subjects gave their i
informed consent. The study was approved by the local ethics
committee at Karolinska University Hospital. t
1
bStimuli
Neutral and unpleasant images from the international affective pic- u
0ture system (IASP) (Lang et al., 1995) were shown in different pre-
sentation blocks. Each picture was presented for 4 s. There was a i
cdelay of 7 s between the pictures during which a black screen with
a cross was presented. During the fMRI experiment, there was also c
ta jitter added in the delay period, and the stimulus onset asynch-
ronicity was then 11, 12.2, or 13.4 s, respectively. The subjects were f
tinstructed to focus on the cross between the pictures and to con-
tinue to focus centrally during the picture presentation. o
During day 1, there were three different versions of picture pre-
sentation blocks. These were randomly assigned to presentation r
1block 1, 2, or 3, respectively, for each participant. Thus, there were
no systematic differences in presented pictures for the whole group t
obetween the presentations in which the subjects were untreated
(presentation block 1), the presentation in which the subjects re- t
bceived an anxiolytic treatment (presentation block 2), or the pre-
sentation in which the subjects were treated with the anxiolytic n
bblocker (presentation block 3).
During the fMRI experiment (day 2), six separate presentation 1
dblocks were used for the three sessions (two presentation blocks
in each session, one with the placebo treatment and one with the c
ccontrol treatment). The order of presentation blocks (1 to 6) was
randomly assigned for each subject. t
aEach presentation block consisted of 13 unpleasant and 13 neu-
tral pictures on the first day and 10 unpleasant and 10 neutral pic- a
tures on the second day (i.e., in the fMRI experiment). The pictures
were semirandomly distributed (using a computerized randomizing j
fprocess) in that pictures from the same category were not allowed
to appear more than three times in a row in order to avoid habitua- t
stion effects. Each presentation block included a balanced number
of pictures showing mutilated bodies. There was an uneven distri- a
6bution of faces in the negative (n = 6–7 per session on day 1 and
7–8 per session on day 2) versus the positive pictures (n = 0–1 per s
esession). Some of the activity in the emotional network was thus
biased toward face processing. However, no such bias existed in b
mthe contrasts of interest (i.e., the placebo contrasts), since these
presentations contained a balanced number of neutral and nega- tive pictures in conditions that are compared with each other, i.e.,
lacebo versus control treatment. Information concerning the pic-
ures that were used in the different presentation blocks is available
rom the authors.
xperimental Design
n day 1, a procedure for expectation manipulation was performed
n order to induce a robust placebo effect on day 2. The subjects
iewed three presentation blocks (duration of 4 min 39 s each) of
andomly mixed unpleasant and neutral pictures as described
bove (Figure 1A). The subjects watched the first set of pictures
ithout any prior manipulation (presentation block 1). Before the
econd session (presentation block 2), they received a small dose
f benzodiazepine intravenously (midolazam; manufactured by
lpharma; concentration = 1 mg/ml; dose = 0.015 mg/kg, approxi-
ately 1/2–1/4 of the recommended dose for clinical use; rate of
nfusion = 30 s) through a catheter inserted in the cubital vein. The
ose was optimally set in a pilot study to induce a reliable effect
n emotional perception but to minimize the influence on level of
oncentration, ability to focus, and subjective nonspecific drug ef-
ects. Injection of the active substance was followed by a flush with
ml saline during 10 s. The subjects were told that the treatment
onsisted of a short-lasting anxiolytic drug and that they would
robably perceive the pictures as less unpleasant. Before the final
resentation (presentation block 3), the subjects received a clinical
ose of a benzodiazepine receptor antagonist intravenously (flu-
azenil; manufactured by Roche; manufacturing name = Lanexat;
oncentration = 0.1 mg/ml; dose = 0.25 mg; rate of infusion =
0 s). They were told that this treatment would act as an antidote
nd completely block the effect of the anxiolytic drug. Injection of
he active substance was followed by a flush with 5 ml saline dur-
ng 10 s.
The subjects were fully informed about the three sessions before
he start of the experiment. There was an approximate time lag of
0 min between each presentation block. After each presentation
lock, the subjects rated their average unpleasantness level for the
npleasant pictures using a visual analog scale (VAS) ranging from
to 100, where 0 denoted no unpleasantness and 100 the highest
maginable unpleasantness perception. The scale consisted of a 10
m long line (printed on paper) that the subjects marked with a
ross depending on their rating. A cross that was placed 1 cm from
he start of the line was interpreted as 10 on the VAS. During the
irst day, the subjects also completed personality and mood ques-
ionnaires. These data are not presented in this article due to lack
f space.
In presentation block 2, the anxiolytic treatment decreased the
ating of unpleasantness by 43.1% compared to presentation block
in which the subjects did not receive any treatment. The effect of
he anxiolytic blocker was a less-expressed increase in the rating
f unpleasantness (19.5%; presentation block 3 versus presenta-
ion block 1). Thus, although both the anxiolytic and the anxiolytic
locker treatment may have induced expectations, the effect domi-
ated after the anxiolytic treatment. The degree of expectation has
een shown to be fundamental for the placebo effect (Price et al.,
999). We therefore considered that the anxiolytic treatment in-
uced the most extensive placebo effect, although the blocker
ondition probably also induced a small negative placebo (or no-
ebo) effect. For simplicity, we have termed the placebo manipula-
ion associated with the anxiolytic drug as the “placebo treatment,”
nd the nocebo manipulation associated with the anxiolytic blocker
s the “control treatment.”
On day 2, a placebo manipulation was performed, and the sub-
ects simultaneously underwent fMRI scanning (Figure 1B). The
unctional scanning consisted of three sessions of two presenta-
ion blocks each (i.e., six presentation blocks in total). Each pre-
entation block contained the same type of unpleasant and pleas-
nt pictures as was shown on day 1, during a period of 4 min and
.4 s. The subjects were informed that they would be given the
ame pharmacological treatment as on the previous day before
ach new presentation block (i.e., the anxiolytic or the anxiolytic
locker treatment). They were also told that the effect of each treat-
ent was only short lasting and that they would therefore be
reated several times with each drug. Finally, they were informed
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blocker in the same way that the blocker could suppress the ef-
fects of the anxiolytic drug. An information text indicating the forth-
coming treatment and its probable result on emotional perception
was exhibited before each presentation on a computer screen in
order to induce a strong expectation of the drug effect. As on day
1, the subjects had an intravenous catheter, and they could clearly
perceive when the “drug” was administered, i.e., when it was
flushed with saline. As the information was presented for 52 s, 5 ml
saline was simultaneously injected intravenously. The rate of injec-
tion and the volume was the same as during day 1 for each specific
substance and saline flush. Each experiment was comprised of
three presentation blocks of neutral and unpleasant pictures in
which expectation of anxiety relief was induced (placebo condition)
and three similar presentation blocks in which no such expectation
was present, but possibly a small negative expectation, i.e., no-
cebo (control condition). There were two orders (A and B) of the
conditions in the three sessions that were randomly assigned to
the different subjects:
A. Session 1: (a) placebo condition, (b) control condition. Session
2: (a) control condition, (b) placebo condition. Session 3: (a) pla-
cebo condition, (b) control condition.
B. Session 1: (a) control condition, (b) placebo condition. Session
2: (a) placebo condition, (b) control condition. Session 3: (a) con-
trol condition, (b) placebo condition.
Thus, some subjects began with the control condition in order to
avoid order effects in the group analysis. All subjects were in-
formed that it was possible to begin with the anxiolytic blocker
condition because of order effects (which is not intuitive) and to
avoid induction of any surprise during the experiment. The re-
searcher injecting the saline was not aware of the order of the con-
ditions. As stated above (see “Stimuli”), the order of the six dif-
ferent picture presentation blocks was randomized for each
subject. After the fMRI sessions, each subject underwent a debrief-
ing session and rated their average unpleasantness level (VAS—as
explained above) elicited by the unpleasant pictures after treatment
with the anxiolytic (i.e., placebo) drug and anxiolytic blocker (i.e.,
control) drug. Each subject also had to indicate verbally whether
there was an effect on emotional perception during different condi-
tions and the nature of any difference (i.e., increased, decreased,
or unchanged perception of unpleasantness).
Image Acquisition
We measured blood oxygen level-dependent (BOLD) responses
using T2*-weighted echoplanar images (EPI) and a GE-1.5 T MR-
scanner. Every image volume consisted of 32 slices with a thick-
ness of 4.2 mm and an interslice gap of 0.3 mm. The field of view
was 220 × 220 mm. The Echo time (TE) was 40 ms, and the repeti-
tion time (TR) was 3.2 s. A total of 510 images was collected over
three sessions of 9.54 min each. Each session started with the first
presentation block and ended after the second presentation block.
An initial high-resolution T1-weighted anatomical image of the
brain was also scanned. This structural image was used in the pre-
processing for coregistration with the mean EPI images for each
subject.
Image Analysis
The fMRI data were analyzed using SPM99 software (Friston et
al., 1995) (http://www.fil.ion.ucl.ac.uk/spm). The fMRI images were
spatially realigned, corrected for slice timing effects, coregistered
with the anatomical scan, normalized to the Montreal Neurological
Institute template, and smoothed with a Gaussian kernel of 8 mm
full-width half-maximum (FWHM). Each picture presentation was
modeled as a discrete event convolved with the canonical hemody-
namic response function (HRF). Depending upon whether the con-
dition was a placebo or a control condition, four different types
of regressors were formed: (1) unpleasant pictures and placebo
treatment (UP), (2) neutral pictures and placebo treatment (NP), (3)
unpleasant pictures and control treatment (UC), and (4) neutral pic-
tures and control treatment (NC). Temporal derivatives of these
regressors were included in the analysis to account for residualvariance in latency. A high-pass filter was used to remove low-
frequency noise.
All contrasts were first analyzed for each individual using SPM99.
We then made three different second-level analyses of the event-
related fMRI data using a random-effects model of one-sample t
tests in SPM99, thereby implementing a random-effects analysis
through the summary statistic approach. In the first analysis, we
considered the whole group in order to find effects that were appli-
cable to the population in general and that would support the be-
havioral data for the whole group. The second analysis was applied
specifically to the placebo responders, which may be more relevant
for the mechanisms involved in the effective placebo response. The
third analysis looked at correlations between the subjective degree
of placebo response (reported in the debriefing session, i.e., rating
of unpleasantness for the unpleasant pictures after the control ver-
sus the placebo treatment) and activations due to placebo. A sim-
ilar correlation analysis was performed for the treatment expecta-
tions.
All subjects took part in the group analysis, while 11 were in-
cluded in the analysis for the subgroup of placebo responders. In
the correlation analysis, one of the 15 subjects could not be in-
cluded because the behavioral data were lost.
All data relating to the placebo response reported here belong to
a small a priori defined network. This network included the ex-
trastriate cortex and the amygdala bilaterally in the (UC − UP) con-
trasts and the interaction analysis ((UC − UP) − (NC − NP)), i.e.,
regions that are involved in emotional processing and that we ex-
pected to be attenuated in the placebo condition. To ensure that
all the regions belonged to the network involved in emotional pro-
cessing, they also had to survive a masking in the main effect of
emotion contrast (UP + UC) − (NP + NC) set at a threshold of p <
0.05 (uncorrected). In the contrasts of (UP − UC) and the interaction
analysis of ((UP − UC) − (NP − NC)), we included the rACC, the
lObfc/vlPFC, and the ventral striatum in our a priori defined network
(the reasoning why these regions are included is stated in the core
text). We report all activations surviving a threshold of uncorrected
p value < 0.005 in these regions and their t values.
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